

# Assessment of epithelial permeability in asthma through nuclear imaging

<b>Submission date</b> 12/06/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/07/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 23/05/2016	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Joy Conway

**Contact details**  
Department of Nuclear Medicine  
D Level, Southampton General Hospital  
Tremona Road  
Southampton  
United Kingdom  
SO16 6YD  
-  
jhc@soton.ac.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
RHM MED0880

# Study information

## Scientific Title

Assessment of epithelial permeability in asthma through nuclear imaging: an observational trial

## Study objectives

This study aims to assess whether the increased epithelial permeability seen on a cellular level in asthma can be assessed using nuclear imaging means. It will look at the clearance from the lungs of two radio-labelled compounds, one which can be absorbed through the bronchial epithelium and one which cannot be absorbed. The latter will be used to correct for mucociliary clearance as a route of clearance from the lungs. The study will involve a control group of healthy people, a group of smokers (in whom epithelial permeability has been demonstrated using this method) and a group of asthmatics to test the hypothesis (both controlled and uncontrolled). Uncontrolled asthmatics will only be enrolled if previous analysis of the data from controlled asthmatics confirms both safety and statistical significance.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Southampton and SouthWest Hampshire Local Research Ethics Committee (LREC) - approval pending as of 12/06/2009

## Study design

Observational case-control study

## Primary study design

Observational

## Secondary study design

Case-control study

## Study setting(s)

Hospital

## Study type(s)

Screening

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Asthma

## Interventions

This is a single centre study occurring at Southampton Hospital. The study will consist of a screening visit, followed by an imaging visit. Three groups (healthy controls, smokers and asthmatics), with 10 patients in each group, will take part. If a preliminary analysis shows statistical significance and safety, the study will be extended to include a further 10

uncontrolled asthmatic patients. The study will consist of a screening visit followed by two imaging visits.

#### Screening visit:

A screening visit will occur to assess eligibility and stability. At the visit, written consent will be taken, medical history and physical examination will be performed. Lung function testing including provocation tests and exhaled NO measurement will also occur. Blood tests to establish normal renal function will be taken. Electronic recording of lung sounds will be performed. For smokers, a record of number of cigarettes smoked per day will be taken, and 'pack years' calculated (wherein a person smoking 20 cigarettes/day for 1 year = 1 pack year, 40 cigarettes/day for 1 year = 2 pack years, etc). A detailed asthmatic history will be taken from asthma patients including symptoms, medication use and completion of an asthma control questionnaire. It is estimated that this visit will last 2 hours.

#### Imaging visit A:

The participant will then return between 14 and 28 days later for their imaging visit. This will firstly consist of a transmission scan to define the lung contours and regions of interest in the lungs, and also allow correction for tissue attenuation of gamma rays. Radiopharmaceuticals will be prepared and nebulised as detailed below. Scintigraphy will occur with the patient in the supine position, with dynamic imaging (1 minute timeframe) for the first hour, together with further images at 60, 90 and 120 minutes. A cumulative urine sample will be collected at 2 hours. A detailed record of number of cigarettes smoked in the preceding 24 hours will be taken from the smoking subjects, whilst a detailed record of asthma medication use in the preceding 24 hours will be taken from the asthmatics. Spirometry and oximetry will be undertaken before and after imaging. It is estimated that this visit will last 3 - 4 hours.

#### Imaging visit B:

The patient will return 24 hours later for further scintigraphic imaging and a 24 hours cumulative urine specimen. Spirometry and oximetry will be undertaken before and after imaging. It is estimated that this visit will last 1 hour.

Follow-up will cease after the second visit, therefore will only last 4 - 5 weeks.

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome measure**

Measurement of clearance of Indium 111-labelled DTPA from the lungs of healthy controls, smokers and asthmatics, measured at the time of the imaging visits, between 14 and 28 days from their screening visit.

### **Secondary outcome measures**

1. Measurement of mucociliary clearance using technetium labelled albumin as a microcolloid, <sup>99m</sup>Tc-Nanocoll, in normal subjects, asthmatics and smokers and comparison for statistically significant difference
2. Lung function and volume measurements (FEV1, forced vital capacity [FVC], forced mid-expiratory flow rate [FEF25-75], reversibility with salbutamol, functional residual capacity [FRC] and total lung capacity [TLC]) together with provocation testing (PC20 metacholine) and exhaled

nitric oxide (eNO) will be recorded and correlated with degree of permeability if possible

3. History of atopy will be recorded and correlated with permeability

4. Lung sounds will be recorded for analysis and correlation with airflow obstruction

Measured at the time of the imaging visits, between 14 and 28 days from their screening visit.

### **Overall study start date**

01/07/2009

### **Completion date**

01/10/2009

## **Eligibility**

### **Key inclusion criteria**

General:

1. Subject must understand the procedures of the study and agree to participation in the study by providing written informed consent
2. Subject considered fit enough to undergo lung function testing including provocation tests
3. Either gender
4. Age 18 - 55 years at screening

Group specific:

1. Healthy controls:

- 1.1. Lifelong non-smoker
- 1.2. No history suggestive of airways disease
- 1.3. Normal spirometry, normal exhaled nitric oxide (NO), provocative concentration causing a 20% fall in forced expiratory volume in one second (FEV1) (PC20) (metacholine) greater than 8 mg/ml (non-cumulative)
- 1.4. No signs of concurrent respiratory infection at time of scanning or within previous 8 weeks
- 1.5. No significant cardiopulmonary/hepatic or renal co-morbidity

2. Smokers:

- 2.1. Daily smokers of tobacco cigarettes
- 2.2. Normal spirometry, normal exhaled NO, PC20 (metacholine) greater than 8 mg/ml (non-cumulative)
- 2.3. No signs of concurrent respiratory infection at time of scanning or within previous 8 weeks
3. Asthmatics - controlled:
  - 3.1. Asthma defined as per BTS guidelines, on treatment with inhaled corticosteroids +/- long-acting beta-agonists
  - 3.2. Lifelong non-smokers (never smoked)
  - 3.3. Clinically stable with FEV1 greater than 70% post-bronchodilator use, with use of rescue bronchodilators less than 3 x week
  - 3.4. No signs of concurrent respiratory infection at time of scanning or within previous 8 weeks
4. Asthmatics - uncontrolled:
  - 4.1. Asthma defined as per BTS guidelines, on treatment with inhaled corticosteroids +/- long-acting beta-agonists
  - 4.2. Lifelong non-smokers (never smoked)
  - 4.3. Use of rescue bronchodilator greater than 3 times a week
  - 4.4. No signs of concurrent respiratory infection at time of scanning or within previous 8 weeks

### **Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Upper age limit**

55 Years

**Sex**

Both

**Target number of participants**

40 (10 in each group, with enrolment of 10 uncontrolled asthmatics only if study shows significance)

**Key exclusion criteria**

1. Pregnancy (where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin [hCG] laboratory test greater than 5 mIU/ml), an intention to become pregnant or breast-feeding (lactating)
2. Subjects with active lung disease other than asthma
3. Significant medical co-morbidity which in the view of the investigator could impact on the interpretation of results or participation in the trial
4. Active cancer or a history of cancer or radiotherapy
5. Current/previous users of recreational inhaled illicit drugs, e.g. cannabis, crack cocaine, etc.
6. Inability to lie flat for scan for 2 hours
7. Those who have participated in a clinical trial involving an investigational or marketed drug within 12 weeks of screening, or participated in any study involving radiation within 12 months of screening
8. Those in any situation which, in the opinion of the investigator, may interfere with optimal participation in the study
9. Those unable to optimally perform the breathing manoeuvres required for lung function testing, or deposition of the radio-labelled aerosol
10. Signs of concurrent respiratory tract infection on examination at the time of scanning or within previous 8 weeks (can be rescreened after 8 weeks if otherwise eligible)

**Date of first enrolment**

01/07/2009

**Date of final enrolment**

01/10/2009

**Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**  
**Department of Nuclear Medicine**  
Southampton  
United Kingdom  
SO16 6YD

## Sponsor information

**Organisation**  
Southampton University Hospitals NHS Trust (UK)

**Sponsor details**  
Research and Development  
Duthie Building (Trust) MP138  
Southampton General Hospital  
Tremona Road  
Southampton  
England  
United Kingdom  
SO16 6YD  
+44 (0)2380 794 149  
katie.benjamin@suht.swest.nhs.uk

**Sponsor type**  
Hospital/treatment centre

**Website**  
<http://www.suht.nhs.uk/home.aspx>

**ROR**  
<https://ror.org/0485axj58>

## Funder(s)

**Funder type**  
Hospital/treatment centre

**Funder Name**  
Southampton General Hospital (UK) - Biomedical Research Unit

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration